{"id":960,"date":"2023-06-15T17:00:09","date_gmt":"2023-06-15T15:00:09","guid":{"rendered":"https:\/\/belgium.easo.org\/?p=960"},"modified":"2024-02-07T15:53:21","modified_gmt":"2024-02-07T14:53:21","slug":"plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/belgium.easo.org\/fr\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/","title":{"rendered":"PlexusENDmore - Code de conduite pour l'utilisation des agonistes du GLP-1 chez les personnes souffrant d'ob\u00e9sit\u00e9 et de diab\u00e8te de type 2"},"content":{"rendered":"<p>Nous nous opposons \u00e0 l'inscription de Novo Nordisk au 1er juin 2023 sur la base des informations fournies dans le cadre de l'AGCS.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>R\u00e8glement relatif \u00e0 la protection des consommateurs (DHCP)<\/li>\n\n\n\n<li>Saxenda\u00ae (liraglutide) en injection dans un stylo \u00e0 bille (FlexTouch\u00ae) : rapport d'\u00e9valuation<\/li>\n<\/ul>\n\n\n\n<p>Raison d'\u00eatre :<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>L'importance de l'efficacit\u00e9 des agonistes du GLP-1 pour les patients souffrant d'ob\u00e9sit\u00e9 afin de garantir la continuit\u00e9 du traitement et de tenir compte du contexte humain de l'efficacit\u00e9 de l'efficacit\u00e9 des agonistes du GLP-1 pour les personnes souffrant d'ob\u00e9sit\u00e9 ou de diab\u00e8te de type 2.<\/li>\n\n\n\n<li>L'uniformisation de la prise en charge de l'ob\u00e9sit\u00e9 dans la r\u00e9gion a permis \u00e0 de nombreux patients de b\u00e9n\u00e9ficier d'une prise en charge m\u00e9dicamenteuse pour le traitement de l'ob\u00e9sit\u00e9.<\/li>\n<\/ol>\n\n\n\n<p>La priorit\u00e9 est donn\u00e9e \u00e0 l'indication de la dur\u00e9e de vie pour l'utilisation des agonistes du GLP-1 :<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Dans le cadre de PlexusENDmore, nous recommandons l'utilisation d'agonistes du GLP-1 dans le cadre de la troisi\u00e8me indication b\u00eata : c'est-\u00e0-dire diab\u00e8te de type 2 avec IMC \u2265 30 kg\/m2 et HbA1c &gt; 7,5% et traitement pendant 10 minutes sur 3 ans avec un ou plusieurs antidiab\u00e9tiques.<\/li>\n\n\n\n<li>Lorsque les patients pr\u00e9sentent un effet th\u00e9rapeutique important dans l'indication finale, il est pr\u00e9f\u00e9rable de les orienter vers d'autres th\u00e9rapies, m\u00eame si cela n'est pas n\u00e9cessaire, et ce, sur la base de l'\u00e9valuation clinique du patient par rapport \u00e0 l'art comportemental.<\/li>\n<\/ol>\n\n\n\n<p>Les personnes qui prennent des agonistes du GLP-1 en quantit\u00e9 importante :<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Les personnes qui utilisent des agonistes du GLP-1 en grande quantit\u00e9 pour obtenir des gains de poids et qui ont obtenu l'effet th\u00e9rapeutique le plus important (&gt;5% de r\u00e9duction de poids), doivent faire l'objet d'une \u00e9valuation afin de d\u00e9terminer si la dose est trop faible ou si elle est trop co\u00fbteuse par rapport \u00e0 l'effet th\u00e9rapeutique. Des mesures individuelles doivent \u00eatre prises sur la base du comportement clinique de la personne par rapport \u00e0 l'art comportemental.<\/li>\n\n\n\n<li>Les personnes qui consomment beaucoup d'agonistes du GLP-1 pour obtenir des gains, mais qui n'ont pas encore obtenu l'effet th\u00e9rapeutique maximal (&lt;5% de r\u00e9duction de la masse corporelle), doivent cesser d&#039;utiliser les agonistes du GLP-1.<\/li>\n<\/ol>\n\n\n\n<p>Les personnes concern\u00e9es ne consomment pas d'agonistes du GLP-1 :<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>L'utilisation des agonistes du GLP-1 n'est pas la premi\u00e8re \u00e9tape dans le traitement de l'ob\u00e9sit\u00e9.<\/li>\n\n\n\n<li>Actuellement, dans notre r\u00e9gion, nous avons commenc\u00e9 \u00e0 traiter de nouveaux patients avec des agonistes du GLP-1 pour l'indication de la prise en charge des maladies.<\/li>\n\n\n\n<li>Dans les cas d'ob\u00e9sit\u00e9 persistante et invalidante (EOSS 3-4), o\u00f9 d'autres options th\u00e9rapeutiques sont possibles, il est possible d'agir sur une base individuelle pour que les agonistes du GLP-1 soient pris en compte dans le cadre de l'\u00e9valuation de l'efficacit\u00e9 du traitement.<\/li>\n<\/ol>\n\n\n\n<p>Nous voulons que ce code de conduite soit respect\u00e9, m\u00eame s'il est important pour la r\u00e9ussite de Wegovy sur le march\u00e9 belge.<\/p>\n\n\n\n<p>Conclusion :<br>Ce code de conduite a pour objectif d'assurer le respect de l'interdiction des agonistes du GLP-1 chez les personnes souffrant d'ob\u00e9sit\u00e9 ou de diab\u00e8te de type 2, et de garantir un niveau de vie \u00e9lev\u00e9 dans la r\u00e9gion.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.bcfi.be\/nl\/chapters\/21?frag=25395&amp;trade_family=32870\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.bcfi.be\/nl\/chapters\/21?frag=25395&amp;trade_family=32870<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Wij verwijzen hiermee naar het schrijven van Novo Nordisk van 1 juni 2023 omtrent informatie verstrekt onder het gezag van het FAGG Rationale: Prioriteit geven aan de terugbetaalde indicatie voor het gebruik van GLP-1 agonisten: Indien personen reeds GLP-1 agonisten gebruiken: Indien personen nog geen GLP-1 agonisten gebruiken: We wensen deze code of conduct aan [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":907,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1,16],"tags":[],"class_list":["post-960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-baso","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes - The Belgian Association for the Study of Obesity<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/belgium.easo.org\/fr\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes - The Belgian Association for the Study of Obesity\" \/>\n<meta property=\"og:description\" content=\"Wij verwijzen hiermee naar het schrijven van Novo Nordisk van 1 juni 2023 omtrent informatie verstrekt onder het gezag van het FAGG Rationale: Prioriteit geven aan de terugbetaalde indicatie voor het gebruik van GLP-1 agonisten: Indien personen reeds GLP-1 agonisten gebruiken: Indien personen nog geen GLP-1 agonisten gebruiken: We wensen deze code of conduct aan [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/posts\/960\" \/>\n<meta property=\"og:site_name\" content=\"The Belgian Association for the Study of Obesity\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-15T15:00:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-07T14:53:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/belgium.easo.org\/wp-content\/uploads\/2023\/06\/Schermafbeelding-2023-06-15-110831.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"206\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"BASO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BASO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/\"},\"author\":{\"name\":\"BASO\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/#\\\/schema\\\/person\\\/d1bc013f37494e62204502c1aaa12b2c\"},\"headline\":\"PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes\",\"datePublished\":\"2023-06-15T15:00:09+00:00\",\"dateModified\":\"2024-02-07T14:53:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/\"},\"wordCount\":437,\"image\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/basocdn.easo.org\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Schermafbeelding-2023-06-15-110831.png?strip=all\",\"articleSection\":[\"BASO\",\"News\"],\"inLanguage\":\"fr-BE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/\",\"name\":\"PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes - The Belgian Association for the Study of Obesity\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/basocdn.easo.org\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Schermafbeelding-2023-06-15-110831.png?strip=all\",\"datePublished\":\"2023-06-15T15:00:09+00:00\",\"dateModified\":\"2024-02-07T14:53:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/#\\\/schema\\\/person\\\/d1bc013f37494e62204502c1aaa12b2c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"fr-BE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-BE\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/basocdn.easo.org\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Schermafbeelding-2023-06-15-110831.png?strip=all\",\"contentUrl\":\"https:\\\/\\\/basocdn.easo.org\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Schermafbeelding-2023-06-15-110831.png?strip=all\",\"width\":772,\"height\":206,\"caption\":\"a computer screen with a text description on it.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/belgium.easo.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/#website\",\"url\":\"https:\\\/\\\/belgium.easo.org\\\/\",\"name\":\"The Belgian Association for the Study of Obesity\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/belgium.easo.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-BE\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/#\\\/schema\\\/person\\\/d1bc013f37494e62204502c1aaa12b2c\",\"name\":\"BASO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-BE\",\"@id\":\"https:\\\/\\\/belgium.easo.org\\\/wp-content\\\/litespeed\\\/avatar\\\/cf429032d661a46da48d28ed93b80656.jpg?ver=1778146303\",\"url\":\"https:\\\/\\\/belgium.easo.org\\\/wp-content\\\/litespeed\\\/avatar\\\/cf429032d661a46da48d28ed93b80656.jpg?ver=1778146303\",\"contentUrl\":\"https:\\\/\\\/belgium.easo.org\\\/wp-content\\\/litespeed\\\/avatar\\\/cf429032d661a46da48d28ed93b80656.jpg?ver=1778146303\",\"caption\":\"BASO\"},\"sameAs\":[\"http:\\\/\\\/belgium.easo.org\"],\"url\":\"https:\\\/\\\/belgium.easo.org\\\/fr\\\/author\\\/chris101\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PlexusENDmore - Code de conduite pour l'utilisation des agonistes du GLP-1 chez les personnes atteintes d'ob\u00e9sit\u00e9 et de diab\u00e8te de type 2 - Association Belge pour l'Etude de l'Ob\u00e9sit\u00e9","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/belgium.easo.org\/fr\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/","og_locale":"fr_FR","og_type":"article","og_title":"PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes - The Belgian Association for the Study of Obesity","og_description":"Wij verwijzen hiermee naar het schrijven van Novo Nordisk van 1 juni 2023 omtrent informatie verstrekt onder het gezag van het FAGG Rationale: Prioriteit geven aan de terugbetaalde indicatie voor het gebruik van GLP-1 agonisten: Indien personen reeds GLP-1 agonisten gebruiken: Indien personen nog geen GLP-1 agonisten gebruiken: We wensen deze code of conduct aan [&hellip;]","og_url":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/posts\/960","og_site_name":"The Belgian Association for the Study of Obesity","article_published_time":"2023-06-15T15:00:09+00:00","article_modified_time":"2024-02-07T14:53:21+00:00","og_image":[{"width":772,"height":206,"url":"https:\/\/belgium.easo.org\/wp-content\/uploads\/2023\/06\/Schermafbeelding-2023-06-15-110831.png","type":"image\/png"}],"author":"BASO","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BASO","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/#article","isPartOf":{"@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/"},"author":{"name":"BASO","@id":"https:\/\/belgium.easo.org\/#\/schema\/person\/d1bc013f37494e62204502c1aaa12b2c"},"headline":"PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes","datePublished":"2023-06-15T15:00:09+00:00","dateModified":"2024-02-07T14:53:21+00:00","mainEntityOfPage":{"@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/"},"wordCount":437,"image":{"@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/basocdn.easo.org\/wp-content\/uploads\/2023\/06\/Schermafbeelding-2023-06-15-110831.png?strip=all","articleSection":["BASO","News"],"inLanguage":"fr-BE"},{"@type":"WebPage","@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/","url":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/","name":"PlexusENDmore - Code de conduite pour l'utilisation des agonistes du GLP-1 chez les personnes atteintes d'ob\u00e9sit\u00e9 et de diab\u00e8te de type 2 - Association Belge pour l'Etude de l'Ob\u00e9sit\u00e9","isPartOf":{"@id":"https:\/\/belgium.easo.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/basocdn.easo.org\/wp-content\/uploads\/2023\/06\/Schermafbeelding-2023-06-15-110831.png?strip=all","datePublished":"2023-06-15T15:00:09+00:00","dateModified":"2024-02-07T14:53:21+00:00","author":{"@id":"https:\/\/belgium.easo.org\/#\/schema\/person\/d1bc013f37494e62204502c1aaa12b2c"},"breadcrumb":{"@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/#breadcrumb"},"inLanguage":"fr-BE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"fr-BE","@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/#primaryimage","url":"https:\/\/basocdn.easo.org\/wp-content\/uploads\/2023\/06\/Schermafbeelding-2023-06-15-110831.png?strip=all","contentUrl":"https:\/\/basocdn.easo.org\/wp-content\/uploads\/2023\/06\/Schermafbeelding-2023-06-15-110831.png?strip=all","width":772,"height":206,"caption":"a computer screen with a text description on it."},{"@type":"BreadcrumbList","@id":"https:\/\/belgium.easo.org\/plexusendmore-code-of-conduct-voor-het-gebruik-van-glp-1-agonisten-bij-personen-met-obesitas-zonder-type-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/belgium.easo.org\/"},{"@type":"ListItem","position":2,"name":"PlexusENDmore \u2013 Code of conduct voor het gebruik van GLP-1 agonisten bij personen met obesitas zonder type 2 diabetes"}]},{"@type":"WebSite","@id":"https:\/\/belgium.easo.org\/#website","url":"https:\/\/belgium.easo.org\/","name":"L'Association belge pour l'\u00e9tude de l'ob\u00e9sit\u00e9","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/belgium.easo.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-BE"},{"@type":"Person","@id":"https:\/\/belgium.easo.org\/#\/schema\/person\/d1bc013f37494e62204502c1aaa12b2c","name":"BASO","image":{"@type":"ImageObject","inLanguage":"fr-BE","@id":"https:\/\/belgium.easo.org\/wp-content\/litespeed\/avatar\/cf429032d661a46da48d28ed93b80656.jpg?ver=1778146303","url":"https:\/\/belgium.easo.org\/wp-content\/litespeed\/avatar\/cf429032d661a46da48d28ed93b80656.jpg?ver=1778146303","contentUrl":"https:\/\/belgium.easo.org\/wp-content\/litespeed\/avatar\/cf429032d661a46da48d28ed93b80656.jpg?ver=1778146303","caption":"BASO"},"sameAs":["http:\/\/belgium.easo.org"],"url":"https:\/\/belgium.easo.org\/fr\/author\/chris101\/"}]}},"_links":{"self":[{"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/posts\/960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/comments?post=960"}],"version-history":[{"count":2,"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/posts\/960\/revisions"}],"predecessor-version":[{"id":1155,"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/posts\/960\/revisions\/1155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/media\/907"}],"wp:attachment":[{"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/media?parent=960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/categories?post=960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/belgium.easo.org\/fr\/wp-json\/wp\/v2\/tags?post=960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}